Nick has spent his entire career in healthcare and life sciences and joined Catalyst as Chief Executive Officer in October 2018. For 21 years prior to joining Catalyst, Nick has worked in the clinical research space with Quintiles (now IQVIA) and PPD Development leading clinical operations, finance, IT, and sales/marketing functions. In 2011, he joined Novella Clinical as Chief Commercial Officer, and in 2016, he was appointed President. While at Novella, Nick fervently embraced the need for therapeutically focused clinical research organization (CRO) solutions interlaced with a flexible small biotech customer service model.

Nick earned his bachelor’s degree in London, England, then completed a three-year postgraduate program with the National Health Service (NHS) working in various healthcare and healthcare management settings. From there, Nick went on to lead the Support Services Finance Group for a large hospital in the southern part of England.

Nick is passionate about soccer (aka football in his native England) and played for club, regional, school, and university teams. He continues to pass down his love of football to his sons Eric and Harrison and spends significant time coaching and watching them play. Nick also loves to cook, watch movies, and read.

Nik joined Catalyst in April 2022 as its Chief Operating Officer. He started his career as a biostatistician with Smithkline Beecham (now GSK) where he worked for nearly seven years before joining PPD. While at PPD, Nik spent four years in project management, leading the hematology and oncology portfolio for two. In 2010 he accepted the global leadership role for biostatistics and programming. In 2016 Nik became Senior Vice President, Site and Patient Access, leading the newly formed global function accountable for selecting and activating sites and accelerating clinical trial access for patients across all therapeutic areas.

In January 2020, Nik launched a new business unit focused on the design and implementation of digitally enabled and decentralized trials. The timing coincided with the Covid-19 pandemic, which introduced extreme demand for solutions from this new startup. Nik led the significant growth of that group and the establishment of those solutions.